
SK Group Chairman Chey Tae-won himself will personally explain to South Korea’s antitrust watchdog his reasons why his 253.3 billion won ($214.4 million) stock purchase four years ago was legitimate, reported The Investor.
According to the Fair Trade Commission Dec. 12, the head of the nation’s third-largest conglomerate is scheduled to voluntarily appear before the antitrust regulator on Dec. 15. The 61-year-old tycoon is expected to deliver his defense over allegations that he illegally benefited and plundered corporate profits through the stock purchase.
In January 2017, SK, the holdings firm of SK Group, acquired 51 percent of LG Siltron, a silicon wafer manufacturer, for 620 billion won.
Three months later, SK acquired another 19.6 percent of LG Siltron, but stopped there. This allowed Chey — chairman and co-CEO of SK — to purchase the remaining 29.4 percent of LG Siltron shares at 253.3 billion won.
As a holding company, SK’s main revenue comes from dividends. It faces accusations that by letting Chey purchase the 29.4 percent, it deliberately gave up a business opportunity to receive more dividends and yielded it to the chairman.
SK claims that it didn’t purchase the 29.4 percent because it didn’t have to. The 70.6 percent, which is more than two-thirds of total shares, gives SK Inc. enough voting rights to pass a special resolution.
Featured News
Judge Orders Apple to Address Fortnite App Block or Face Court Hearing
May 19, 2025 by
CPI
EU Civil Society Groups and Labor Unions Raise Alarm Over Proposed Changes to GDPR
May 19, 2025 by
CPI
EU Antitrust Regulators Push Back Deadline on UniCredit’s Takeover Bid for Banco BPM
May 19, 2025 by
CPI
Intel Challenges €376 Million EU Fine in Ongoing Antitrust Dispute
May 19, 2025 by
CPI
Red Bull Challenges EU Commission Over Lengthy Antitrust Inspection
May 19, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas